• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Caribou Biosciences Files up to $100M IPO

firstwordpharmaJuly 02, 2021

Tag: Caribou Biosciences , IPO , chRDNA

Caribou Biosciences has filed for an initial public offering of $100 million, reported StreetInsider.

The company is working on applying its hybrid RNA-DNA CRISPR platform (chRDNA) toward the development of next-generation, genome-edited cell therapies.

Caribou says its chRDNA technology has demonstrated superior specificity and high efficiency in preclinical studies, enabling multiple, precise genomic edits, while maintaining genomic integrity.

Previous:Bioasis Announces the Appointment of Dave Jenkins as CFO

Next:Cidara Therapeutics Provides Leadership Update

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Caribou Biosciences Files up to $100M IPO | Pharmasources.com

Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA

PR NEWSWIRENovember 22, 2024

Ascentage Pharma announced that a NDA for its inhouse developed investigational novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575)has been accepted and recommended the Priority Review designation CDE and NMPA.

You may like
More>>

4'-Demethylepipodophyllotoxin

4'-Demethylepipodophyllotoxin
DIPOTASSIUM CETYL PHOSPHATE

DIPOTASSIUM CETYL PHOSPHATE

LDS-L1 TANGENTIAL FLOW FILTRATION/Liposome dialysis / LNP dialysis

LDS-L1 TANGENTIAL FLOW FILTRATION/Liposome dialysis / LNP dialysis
Lipoic Acid

Lipoic Acid
Geniposide

Geniposide
Potassium Tripolyphosphate

Potassium Tripolyphosphate
Poliporus powder

Poliporus powder
Tripolyglycerol Monostearates

Tripolyglycerol Monostearates
E343(iii)Tripotassium Phosphate Tribasic (ATKP) Anhydrous Favouring Agent

E343(iii)Tripotassium Phosphate Tribasic (ATKP) Anhydrous Favouring Agent
Dipotassium Phosphate

Dipotassium Phosphate

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service